
Arcellx: The Gilead Deal Derisks And Proves Their Technology (NASDAQ:ACLX)
Artur Plawgo Arcellx, Inc. (NASDAQ:ACLX) is up 83% since my bullish coverage from August. Goes to show how biotech is recovering from the slump that was 2022, because this is not a sentence I could […]